SCHEMBL9905935

SCHEMBL9905935

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC(O)COP(=O)(O)O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 8/20 0.72
ENPP2 Q13822 4/20 0.72
LPAR4 Q99677 3/20 0.72
LPAR5 Q9H1C0 3/20 0.72
LPAR2 Q9HBW0 3/20 0.72
LPAR3 Q9UBY5 3/20 0.72
LPAR6 P43657 2/20 0.72
CES2 O00748 1/20 0.72
TRPV1 Q8NER1 1/20 0.72
GPR55 Q9Y2T6 1/20 0.61
FAAH O00519 2/20 0.58
NR1I2 O75469 1/20 0.58
PGR P06401 1/20 0.58
ADORA3 P0DMS8 1/20 0.58
PTGS2 P35354 1/20 0.58
PDE4D Q08499 1/20 0.58
P2RY10 O00398 4/20 0.53
GPR174 Q9BXC1 4/20 0.53
GPR34 Q9UPC5 3/20 0.53
ALDH1A1 P00352 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31442359 0.96 LPAR1 (0.78) LPAR1ENPP2LPAR4LPAR5LPAR2
SCHEMBL13409099 0.95 LPAR1 (0.80) LPAR1ENPP2LPAR4LPAR5LPAR2
SCHEMBL29438562 0.95 LPAR1 (0.80) LPAR1ENPP2LPAR4LPAR5LPAR2
SCHEMBL29438566 0.95 LPAR1 (0.80) LPAR1ENPP2LPAR4LPAR5LPAR2
SCHEMBL6345706 0.95 LPAR1 (0.80) LPAR1ENPP2LPAR4LPAR5LPAR2
SCHEMBL9905951 0.95 LPAR1 (0.80) LPAR1ENPP2LPAR4LPAR5LPAR2
SCHEMBL6340011 0.95 LPAR1 (0.80) LPAR1ENPP2LPAR4LPAR5LPAR2
SCHEMBL6346455 0.95 LPAR1 (0.80) LPAR1ENPP2LPAR4LPAR5LPAR2
SCHEMBL9905960 0.92 LPAR1 (0.64) LPAR1ENPP2LPAR4LPAR5LPAR2
SCHEMBL29438567 0.92 LPAR1 (0.64) LPAR1ENPP2LPAR4LPAR5LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12247981-B2 Method of diagnosing cancer based on lipidomic analysis of a body fluid FONS JK GROUP, A.S. (CZ) 2025-03-11 US disclosed
US-9925165-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof SCF PHARMA INC. (CA) 2018-03-27 US disclosed
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2017-01-19 US disclosed
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2017-01-19 US disclosed
US-9480660-B2 Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof SCF PHARMA INC. (CA) 2016-11-01 US disclosed
US-9480660-B2 Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof SCF PHARMA INC. (CA) 2016-11-01 US disclosed
US-9233915-B2 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof SCF PHARMA INC. (CA) 2016-01-12 US disclosed
US-9233915-B2 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof SCF PHARMA INC. (CA) 2016-01-12 US disclosed
US-9101563-B2 Method for treating an inflammatory disease with compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof SCF PHARMA INC (CA) 2015-08-11 US disclosed
US-9101563-B2 Method for treating an inflammatory disease with compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof SCF PHARMA INC (CA) 2015-08-11 US disclosed
US-8119690-B2 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2012-02-21 US disclosed
US-8119690-B2 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2012-02-21 US disclosed
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2010-08-05 US disclosed
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2010-08-05 US disclosed
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2010-06-24 US disclosed
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2010-06-24 US disclosed
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN LPAR1 248/4885ENPP2 231/4885LPAR4 266/4885
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF FASN, MGLL, FADS1 LPAR1 194/4885ENPP2 186/4885LPAR4 302/4885
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF PPARG, PTGES, PTGIS LPAR1 114/4885ENPP2 116/4885LPAR4 135/4885
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN LPAR1 248/4885ENPP2 231/4885LPAR4 266/4885
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF FASN, MGLL, FADS1 LPAR1 194/4885ENPP2 186/4885LPAR4 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.